US Stock Insider Trading | Spyre Therapeutics disclosed two insider trading transactions on February 4

2026-02-20 13:48:21

On February 4, 2026, Spyre Therapeutics (SYRE) disclosed two insider trading transactions. Director Turtle Cameron sold 15,700 shares on February 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Director	Turtle Cameron	February 2, 2026	Sell	957	31.82	30,500
February 4, 2026	Director	Turtle Cameron	February 2, 2026	Sell	14,000	32.87	461,600
January 6, 2026	Director	Turtle Cameron	January 2, 2026	Sell	2,191	31.79	69,700
January 6, 2026	Director	Turtle Cameron	January 2, 2026	Sell	12,700	30.47	387,200
January 6, 2026	Director	Turtle Cameron	January 2, 2026	Sell	100	32.39	3,239
December 3, 2025	Director	Turtle Cameron	December 1, 2025	Sell	4,005	29.83	119,500
December 3, 2025	Director	Turtle Cameron	December 1, 2025	Sell	11,000	28.73	315,900
November 5, 2025	Director	Turtle Cameron	November 3, 2025	Sell	16,800	23.66	398,600
November 5, 2025	Director	Turtle Cameron	November 3, 2025	Sell	28,200	23.13	651,200
September 3, 2025	Executive	Burrows Scott L	September 2, 2025	Sell	18,400	16.26	299,600

[Company Information]

Spyre Therapeutics, Inc. was converted from a Delaware LLC on December 16, 2013. The company is a biotechnology firm focused on creating next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s product line includes long-acting antibodies targeting α4β7, TL1A, and IL-23.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes